- Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer2009 | First Faculty of Medicine, Faculty of Physical Education and Sport, Third Faculty of Medicine
- Survivin, a novel target of the Hedgehog/GLI signaling pathway in human tumor cells2016 | First Faculty of Medicine